These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27257133)

  • 1. Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation.
    Suda K; Murakami I; Yu H; Ellison K; Shimoji M; Genova C; Rivard CJ; Mitsudomi T; Hirsch FR
    J Thorac Oncol; 2016 Oct; 11(10):1711-7. PubMed ID: 27257133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship between EGFR Mutations and Pathological Classification and 
Specimen of Lung Adenocarcinoma].
    Kang L; Zheng J; Zhu X
    Zhongguo Fei Ai Za Zhi; 2017 Jun; 20(6):382-388. PubMed ID: 28641695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
    Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma.
    Soma S; Tsuta K; Takano T; Hatanaka Y; Yoshida A; Suzuki K; Asamura H; Tsuda H
    Pathol Res Pract; 2014 Mar; 210(3):155-60. PubMed ID: 24355440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining.
    Hashimoto T; Osoegawa A; Takumi Y; Abe M; Kobayashi R; Miyawaki M; Takeuchi H; Okamoto T; Sugio K
    Lung Cancer; 2018 Oct; 124():241-247. PubMed ID: 30268468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential - An Implication of Micropapillary Element.
    Matsumura M; Okudela K; Kojima Y; Umeda S; Tateishi Y; Sekine A; Arai H; Woo T; Tajiri M; Ohashi K
    PLoS One; 2016; 11(11):e0166795. PubMed ID: 27861549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.
    Lee EY; Khong PL; Lee VH; Qian W; Yu X; Wong MP
    Clin Nucl Med; 2015 Mar; 40(3):e190-5. PubMed ID: 25608155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
    Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
    BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Oguri T; Yoshida T; Shimizu J; Horio Y; Hata A; Kaji R; Fujita S; Sekido Y; Kodaira T; Kokubo M; Katakami N; Yatabe Y
    J Thorac Oncol; 2015 Dec; 10(12):1720-5. PubMed ID: 26743855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micropapillary: A component more likely to harbour heterogeneous EGFR mutations in lung adenocarcinomas.
    Cai YR; Dong YJ; Wu HB; Liu ZC; Zhou LJ; Su D; Chen XJ; Zhang L; Zhao YL
    Sci Rep; 2016 Apr; 6():23755. PubMed ID: 27046167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
    Eng J; Woo KM; Sima CS; Plodkowski A; Hellmann MD; Chaft JE; Kris MG; Arcila ME; Ladanyi M; Drilon A
    J Thorac Oncol; 2015 Dec; 10(12):1713-9. PubMed ID: 26334752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.
    Toki MI; Carvajal-Hausdorf DE; Altan M; McLaughlin J; Henick B; Schalper KA; Syrigos KN; Rimm DL
    J Thorac Oncol; 2016 Nov; 11(11):1901-1911. PubMed ID: 27449805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
    Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
    J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
    Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
    Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients.
    Shan L; Wang Z; Guo L; Sun H; Qiu T; Ling Y; Li W; Li L; Liu X; Zheng B; Lu N; Ying J
    Lung Cancer; 2015 Sep; 89(3):337-42. PubMed ID: 26141217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma].
    Wang K; Gong H; Li X; Yang Z; Cao P; Wand C; Jiang Y; Wang H; Wang Y; Zhang G
    Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):170-4. PubMed ID: 26268750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology.
    Sakashita S; Shiba-Ishii A; Murata Y; Sekimoto R; Minami Y; Sato Y; Noguchi M
    Pathol Res Pract; 2018 Aug; 214(8):1224-1230. PubMed ID: 29887244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific expression of MUC21 in micropapillary elements of lung adenocarcinomas - Implications for the progression of EGFR-mutated lung adenocarcinomas.
    Matsumura M; Okudela K; Nakashima Y; Mitsui H; Denda-Nagai K; Suzuki T; Arai H; Umeda S; Tateishi Y; Koike C; Kataoka T; Irimura T; Ohashi K
    PLoS One; 2019; 14(4):e0215237. PubMed ID: 30973916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.